Pacific Edge signs Cxbladder agreement with third national provider network in the US
28th November 2013

Pacific Edge has signed an agreement with Stratose, a large national provider network in the USA, to enable the provision of Cxbladder to patients through its large network of payers and providers. Read More

Pacific Edge signs agreement with America’s Choice Provider Network to expand access to Cxbladder in the US
22nd October 2013

Pacific Edge has signed an agreement with America’s Choice Provider Network (ACPN) to provide more Americans access to Cxbladder. ACPN offers a medical network solution for more than 14 million Americans through its client base consisting of insurance carriers, third party administrators, health and welfare funds, employer groups and self-insured health plans. Read More

First Commercial Sales Achieved for Pacific Edge’s Cxbladder in the USA
18th October 2013

Cancer diagnostic specialist Pacific Edge (NZX:PEB) is delighted to announce that it has completed the first commercial sales of Cxbladder tests signalling the start of the commercial revenue for the company in the US. The tests were ordered by US based clinicians and processed in Pacific Edge USA (PEDUSA)’s custom laboratory in Hershey Pennsylvania. Read More

Cxbladder is Supreme Winner at NZ Innovators Awards
18th October 2013

Pacific Edge is the 2013 Supreme Winner of the NZ Innovators Award for Cxbladder, its novel gene test for the detection and management of bladder cancer. Read More

Pacific Edge Agreement With National Provider Network FedMed Gives 40 Million Americans Access to Cxbladder
16th October 2013

Pacific Edge (NZX:PEB), a cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests, has signed an agreement with FedMed, a national preferred provider network in the United States, to make Cxbladder available to an additional 40 million Americans. Read More

Cxbladder excels in New Zealand
10th September 2013

New Zealand clinicians and healthcare providers are excited about Pacific Edge Limited’s cancer detection system Cxbladder for its ability to detect bladder cancer with a high degree of accuracy. Read More

MidCentral DHB first in New Zealand to utilize Cxbladder
30th May 2013

MidCentral District Health Board, based in Palmerston North, is set to become the first district health board in New Zealand to become a commercial customer for Pacific Edgeʼs diagnostic cancer test Cxbladder. MidCentral will be looking to provide patients with a better clinical outcome as well as make considerable savings and efficiencies from its use. Read More

Pacific Edge's US laboratory receives CLIA registration for Cxbladder
18th March 2013

Cancer diagnostic specialist Pacific Edge has achieved a major milestone with notification that its commercial laboratory in Hershey, Pennsylvania, has gained registration under the CLIA[1] regulatory process clearing the way for the launch of Cxbladder in the United States. Read More

NZTE Video: David Darling discusses roll-out of Cxbladder in the US
01st February 2013

David Darling, Pacific Edge Ltd CEO, discusses roll-out of the Cxbladder test into the United States market with New Zealand Trade and Enterprise (NZTE) at the US Health Immersion Program in Washington DC. Read More